Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Univ. Licenses Barrett’s Esophagus Detection Device

Cancer magnified

A medical device company is licensing a minimally-invasive technology developed in university labs for detection of Barrett’s esophagus, a condition that often leads to esophageal cancer. . . . → Read More: Univ. Licenses Barrett’s Esophagus Detection Device

Genetic Repair Company Starts-Up, Gains $87 Million

David Liu

A company is getting underway to develop therapies that extend genome editing to repair genetic disruptions, not just remove them from DNA. . . . → Read More: Genetic Repair Company Starts-Up, Gains $87 Million

Genentech Gains Microbe Drug Discovery Tech in $1B Deal

Collecting soil samples

Biotechnology company Genentech is licensing a process from a start-up enterprise that discovers small molecule drugs from naturally occurring microbes found in soil. . . . → Read More: Genentech Gains Microbe Drug Discovery Tech in $1B Deal

Lilly, Cell Implants Start-Up Partner on Diabetes

Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases. . . . → Read More: Lilly, Cell Implants Start-Up Partner on Diabetes

New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells. . . . → Read More: New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

Cough Suppressant Produced from Engineered Yeast Cells

A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast. . . . → Read More: Cough Suppressant Produced from Engineered Yeast Cells

Antibodies Licensed for Multi-Target Immunotherapies

MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets. . . . → Read More: Antibodies Licensed for Multi-Target Immunotherapies

Patent Awarded for Nanoparticle Drug, Cannabis Delivery

A delivery technology for therapeutic compounds in nanoscale natural oil particles received a U.S. patent, which the company owning the technology says can be applied to drugs, nutritional supplements, and cannabis-based treatments. . . . → Read More: Patent Awarded for Nanoparticle Drug, Cannabis Delivery

Novartis Licenses Biomaterial for Cancer Immunotherapy

Drug maker Novartis is licensing from a lab at Harvard University a biocompatible material designed to provide delivery of treatments that invoke the immune system to fight cancer. . . . → Read More: Novartis Licenses Biomaterial for Cancer Immunotherapy

Evotec Acquiring Sanofi Infectious Disease Portfolio

Drug discovery company Evotec AG is licensing 10 infectious disease R&D programs and their 100 employees from drug maker Sanofi, and opening new labs for this work in Lyon, France. . . . → Read More: Evotec Acquiring Sanofi Infectious Disease Portfolio